Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

ClinicalTrials.gov ID: NCT03731091

Public ClinicalTrials.gov record NCT03731091. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 2:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd) to the Marketed Product Enstilar® Foam (LEO Pharma Inc.) in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis)

Study identification

NCT ID
NCT03731091
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Enrollment
494 participants

Conditions and interventions

Interventions

  • Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064% Drug
  • Enstilar® foam (LEO Pharma Inc.) Drug
  • Placebo of Calcipotriene/ betamethasone dipropionate topical foam Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 30, 2018
Primary completion
Mar 16, 2020
Completion
Mar 16, 2020
Last update posted
Aug 18, 2020

2018 – 2020

United States locations

U.S. sites
30
U.S. states
14
U.S. cities
27
Facility City State ZIP Site status
Investigational Site 20 Encinitas California 92024
Investigational Site 18 Fountain Valley California 92708
Investigational Site 19 San Diego California 92108
Investigational Site 15 San Diego California 92123
Investigational Site 23 San Diego California 92123
Investigational Site 17 Santa Ana California 92705
Investigational Site 22 Santa Monica California 90404
Investigational Site 29 Clearwater Florida 33761
Investigational Site 27 Coral Gables Florida 33134
Investigational Site 1 Miami Florida 33144
Investigational Site 26 Pinellas Park Florida 33781
Investigational Site 10 New Albany Indiana 47150
Investigational Site 3 Overland Park Kansas 66215
Investigational Site 16 Louisville Kentucky 40241
Investigational Site 21 Saint Joseph Missouri 64506
Investigational Site 12 Henderson Nevada 89052
Investigational Site 28 New York New York 10019
Investigational Site 4 High Point North Carolina 27262
Investigational Site 24 Wilmington North Carolina 28405
Investigational Site 8 Beachwood Ohio 44122
Investigational Site 2 Cincinnati Ohio 45246
Investigational Site 13 Greenville South Carolina 29607
Investigational Site 7 Knoxville Tennessee 37922
Investigational site 31 Murfreesboro Tennessee 37130
Investigational Site 25 Nashville Tennessee 37215
Investigational Site 5 Austin Texas 78759
Investigational Site 11 San Antonio Texas 78213
Investigational Site 14 San Antonio Texas 78249
Investigational Site 30 Webster Texas 77598
Investigational Site 6 Norfolk Virginia 23507

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03731091, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 18, 2020 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03731091 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →